Trial Profile
A Study to Determine the Safety and Efficacy of Famciclovir in the Episodic and Suppressive Treatment of Recurrent Genital Herpes (RGH). The Study Will Also Evaluate Quality of Life and Patient Satisfaction.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 May 2012
Price :
$35
*
At a glance
- Drugs Famciclovir (Primary)
- Indications Herpes genitalis
- Focus Therapeutic Use
- Acronyms RELIEF
- Sponsors Novartis
- 26 Apr 2012 Actual end date (Jun 2005) added as reported by ClinicalTrials.gov.
- 26 Apr 2012 Actual initiation date (Jun 2003) added as reported by ClinicalTrials.gov.
- 26 Apr 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT00219310).